
Longer duration insulin delivery
We are developing a novel drug diffusion technology to increase the wear time and performance of a cannula to support consistent long term insulin pump use for people with type 1 diabetes.

WINNER
of the Viewers Choice Award at the Enterprise Ireland BIG IDEAS 2022
INFUSION SETS NEED TO BE FREQUENTLY CHANGED
UNTIL NOW
UNMET NEED
For people with type 1 diabetes, getting life saving insulin into their body is a lot of work. The development of insulin pump technologies has rapidly evolved over the last 50 years, however, the most important component of this system; infusion sets, have not. Infusion sets have a lifespan of 2 or 3 days and frequently fail within hours of insertion. The short lifespan and high failure rates cause more interruptions to insulin therapy, which are shown to negatively impact blood-glucose control.
Failed cannulas and the insulin discarded within them are also a waste that leads to excessive environmental impact and excessive healthcare spending.

18M
People living with type 1 diabetes (T1D) worldwide
10%
Use Insulin pumps. Low adoption due to unreliability of infusion sets
40%
of users change their infusion set early due to kinking or blocking
30%
of people with T1D would use insulin pumps if infusion sets were more reliable
MISSION
Fada Medical's mission is to optimize chronic drug therapy, making life easier for the people who need it. Starting with insulin delivery for those with type 1 diabetes, Fada Medical are developing diffusion technologies to prevent and negate the causes of early infusion set failure and cannula occlusion that make insulin therapy more difficult.

FEATURES
Raising the Bar


IMPROVED LONGEVITY
OF INSULIN DELIVERY
RESISTANT TO SILENT OCCLUSION
Consistent insulin delivery
for up to 30 days
10x longer than current gold standard
COMPETITIVE ADVANTAGE

MEET THE TEAM
ROBERT WYLIE
CEO
Co-Founder

PROF. GARRY DUFFY
Academic Co-Founder

DR. EIMEAR DOLAN
Academic Co-Founder

PROF ELLEN ROCHE
Academic Co-Founder

PROF DEREK O'KEEFFE
Clinical Advisor

IMPACT
Our technology will have an impact on insulin therapy in a number of different ways:



FOR PATIENTS
Outstanding quality
More comfortable
Better glucose control
Longer lifespan and consistency
FOR CLINICIANS
Reduced patient burden
Improve patient long term outcomes
FOR PAYORS
Eliminate €1billion waste in healthcare industry
Reduce patient hospitalisations
SUPPORTED BY






